全文获取类型
收费全文 | 9805篇 |
免费 | 899篇 |
国内免费 | 369篇 |
专业分类
耳鼻咽喉 | 25篇 |
儿科学 | 141篇 |
妇产科学 | 69篇 |
基础医学 | 587篇 |
口腔科学 | 183篇 |
临床医学 | 2116篇 |
内科学 | 3042篇 |
皮肤病学 | 94篇 |
神经病学 | 734篇 |
特种医学 | 122篇 |
外国民族医学 | 2篇 |
外科学 | 445篇 |
综合类 | 1481篇 |
现状与发展 | 4篇 |
预防医学 | 177篇 |
眼科学 | 60篇 |
药学 | 1126篇 |
3篇 | |
中国医学 | 448篇 |
肿瘤学 | 214篇 |
出版年
2024年 | 20篇 |
2023年 | 132篇 |
2022年 | 151篇 |
2021年 | 282篇 |
2020年 | 357篇 |
2019年 | 352篇 |
2018年 | 346篇 |
2017年 | 369篇 |
2016年 | 377篇 |
2015年 | 371篇 |
2014年 | 484篇 |
2013年 | 788篇 |
2012年 | 506篇 |
2011年 | 452篇 |
2010年 | 416篇 |
2009年 | 404篇 |
2008年 | 361篇 |
2007年 | 400篇 |
2006年 | 318篇 |
2005年 | 354篇 |
2004年 | 288篇 |
2003年 | 303篇 |
2002年 | 266篇 |
2001年 | 278篇 |
2000年 | 248篇 |
1999年 | 222篇 |
1998年 | 211篇 |
1997年 | 184篇 |
1996年 | 162篇 |
1995年 | 182篇 |
1994年 | 162篇 |
1993年 | 117篇 |
1992年 | 113篇 |
1991年 | 117篇 |
1990年 | 105篇 |
1989年 | 86篇 |
1988年 | 99篇 |
1987年 | 83篇 |
1986年 | 61篇 |
1985年 | 113篇 |
1984年 | 104篇 |
1983年 | 71篇 |
1982年 | 77篇 |
1981年 | 63篇 |
1980年 | 46篇 |
1979年 | 21篇 |
1978年 | 12篇 |
1977年 | 13篇 |
1976年 | 14篇 |
1974年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 22 毫秒
131.
Antimicrobial Activity of Platelet‐Rich Plasma and Other Plasma Preparations Against Periodontal Pathogens 下载免费PDF全文
Li‐Chiu Yang Suh‐Woan Hu Min Yan Jaw‐Ji Yang Sing‐Hua Tsou Yuh‐Yih Lin 《Journal of periodontology》2015,86(2):310-318
Background: In addition to releasing a pool of growth factors during activation, platelets have many features that indicate their role in the anti‐infective host defense. The antimicrobial activities of platelet‐rich plasma (PRP) and related plasma preparations against periodontal disease–associated bacteria were evaluated. Methods: Four distinct plasma fractions were extracted in the formulation used commonly in dentistry and were tested for their antibacterial properties against three periodontal bacteria: Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, and Fusobacterium nucleatum. The minimum inhibitory concentration of each plasma preparation was determined, and in vitro time‐kill assays were used to detect their abilities to inhibit bacterial growth. Bacterial adhesion interference and the susceptibility of bacterial adherence by these plasma preparations were also conducted. Results: All plasma preparations can inhibit bacterial growth, with PRP showing the superior activity. Bacterial growth inhibition by PRP occurred in the first 24 hours after application in the time‐kill assay. PRP interfered with P. gingivalis and A. actinomycetemcomitans attachment and enhanced exfoliation of attached P. gingivalis but had no influences on F. nucleatum bacterial adherence. Conclusions: PRP expressed antibacterial properties, which may be attributed to platelets possessing additional antimicrobial molecules. The application of PRP on periodontal surgical sites is advisable because of its regenerative potential and its antibacterial effects. 相似文献
132.
133.
134.
135.
Ibrahim Tohidi‐Esfahani Christine S. M. Lee Hai Po H. Liang Vivien M. Y. Chen 《International journal of laboratory hematology》2020,42(Z1):59-67
Platelets play a critical role in both haemostasis and thrombosis, and it is now evident that not all platelets behave the same when they are called to action. A functionally distinct subpopulation of platelets forms in response to maximal agonist stimulation: the procoagulant platelet. This platelet subpopulation is defined by its ability to expose phosphatidylserine on its surface, allowing for coagulation factor complexes to form and generate bursts of thrombin and fibrin to stabilize platelet clots. Reduced levels of procoagulant platelets have been linked to bleeding in Scott's syndrome and haemophilia A patients, and elevated levels have been demonstrated in many thrombotic disorders, including identifying patients at higher risk for stroke recurrence. One obstacle for incorporating an assay for measuring procoagulant platelets into clinical management algorithms is the lack of consensus on the exact definition and markers for this subpopulation. This review will outline the biological characteristics of procoagulant platelets and the laboratory assays currently used to identify them in research settings. It will summarize the findings of clinical research demonstrating the relevance of measuring the procoagulant platelet levels in patients and will discuss how an appropriate assay can be used to elucidate the mechanism behind the formation of this subpopulation, facilitating novel drug discovery to improve upon current outcomes in cardiovascular and other thrombotic disorders. 相似文献
136.
137.
138.
Kwon-Duk Seo Young Dae Kim Young-Won Yoon Jong-Youn Kim Kyung-Yul Lee 《Yonsei medical journal》2014,55(3):683-688
Purpose
Clopidogrel is metabolized by the hepatic cytochrome P450 (CYP) system into its active thiol metabolite. CYP3A4 is involved in the metabolism of both clopidogrel and dihydropyridine calcium channel blockers (CCBs). A few reports have suggested an inhibitory interaction between CCBs and clopidogrel. Accordingly, the aim of this study was to determine the effect of CCBs on the antiplatelet activity of clopidogrel by serial P2Y12 reaction unit (PRU) measurements.Materials and Methods
We assessed changes in antiplatelet activity in patients receiving both clopidogrel and CCBs for at least 2 months prior to enrollment in the study. The antiplatelet activity of clopidogrel was measured by VerifyNow P2Y12 assay in the same patient while medicated with CCBs and at 8 weeks after discontinuation of CCBs. After discontinuation of the CCBs, angiotensin receptor blockers were newly administered to the patients or dosed up for control of blood pressure.Results
Thirty patients finished this study. PRU significantly decreased after discontinuation of CCBs (238.1±74.1 vs. 215.0±69.3; p=0.001). Of the 11 patients with high post-treatment platelet reactivity to clopidogrel (PRU≥275), PRU decreased in nine patients, decreasing below the cut-off value in seven of these nine patients after 8 weeks. Decrease in PRU was not related to CYP2C19 genotype.Conclusion
CCBs inhibit the antiplatelet activity of clopidogrel. 相似文献139.
Tissue fibrosis, or scar formation, is a common response to damage in most organs of the body. The central nervous system (CNS) is special in that fibrogenic cells are restricted to vascular and meningeal niches. However, disruption of the blood–brain barrier and inflammation can unleash stromal cells and trigger scar formation. Astroglia segregate from the inflammatory lesion core, and the so‐called “glial scar” composed of hypertrophic astrocytes seals off the intact neural tissue from damage. In the lesion core, a second type of “fibrotic scar” develops, which is sensitive to inflammatory mediators. Genetic fate mapping studies suggest that pericytes and perivascular fibroblasts are activated, but other precursor cells may also be involved in generating a transient fibrous extracellular matrix in the CNS. The stromal cells sense inflammation and attract immune cells, which in turn drive myofibroblast transdifferentiation. We believe that the fibrotic scar represents a major barrier to CNS regeneration. Targeting of fibrosis may therefore prove to be a valuable therapeutic strategy for neurological disorders such as stroke, spinal cord injury and multiple sclerosis. 相似文献
140.